| Filed On | Filing |
|---|---|
| 09 Oct 2026 |
Form 4: Graff Jeremy R., See Remarks
Received 48,147 shares by exercise or conversion · Gave up 17,814 shares to cover exercise price or tax ($21K) · Received 39,494 shares by exercise or conversion · 1 more |
| 01 Oct 2026 |
8-K: Other Events
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development |
| 29 Sep 2026 |
8-K: Other Events
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib |
| 16 Sep 2026 |
8-K: Other Events
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development |
| 14 Sep 2026 |
8-K: Other Events
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathwa... |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 14 Aug 2026 | FORM 10-Q |
| 01 Jul 2026 | 8-K: Submission of Matters to a Vote of Security Holders; Other Events |
| 22 Jun 2026 | 8-K: Other Events |
| 02 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 15 May 2026 | FORM 10-Q |
| 14 May 2026 |
Form 4: Jensen Thomas, CEO
Received 200,000 shares as a grant or award |
| 11 May 2026 |
Form 4: Hoeiland Jesper, Director
Received 25,000 shares as a grant or award |
| 11 May 2026 |
Form 3: Hoeiland Jesper, Director
No securities owned |
| 08 May 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 07 May 2026 |
Form 4: McLaughlin Gerald W., Director
Received 45,000 shares as a grant or award |
| 06 May 2026 | 8-K: Other Events |
| 30 Apr 2026 | ANNUAL REPORT |
| 30 Apr 2026 | PROXY STATEMENT |
| 30 Apr 2026 |
Form 4: Ervin Jeffrey S, CFO
Received 150,000 shares as a grant or award |
Loading...
